29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Überversorgung in der Intensivmedizin: erkennen, benennen, vermeiden : Positionspapier der Sektion Ethik der DIVI und der Sektion Ethik der DGIIN Translated title: Overtreatment in intensive care medicine—recognition, designation, and avoidance : Position paper of the Ethics Section of the DIVI and the Ethics section of the DGIIN

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ungeachtet der sozialgesetzlichen Vorgaben existieren im deutschen Gesundheitssystem in der Patientenversorgung nebeneinander Unter‑, Fehl- und Überversorgung. Überversorgung bezeichnet diagnostische und therapeutische Maßnahmen, die nicht angemessen sind, da sie die Lebensdauer oder Lebensqualität der Patienten nicht verbessern, mehr Schaden als Nutzen verursachen und/oder von den Patienten nicht gewollt werden. Daraus können hohe Belastungen für die Patienten, deren Familien, die Behandlungsteams und die Gesellschaft resultieren. Dieses Positionspapier erläutert Ursachen von Überversorgung in der Intensivmedizin und gibt differenzierte Empfehlungen zu ihrer Erkennung und Vermeidung. Zur Erkennung und Vermeidung von Überversorgung in der Intensivmedizin erfordert es Maßnahmen auf der Mikro‑, Meso- und Makroebene, insbesondere die folgenden: 1) regelmäßige Evaluierung des Therapieziels im Behandlungsteam unter Berücksichtigung des Patientenwillens und unter Begleitung von Patienten und Angehörigen; 2) Förderung einer patientenzentrierten Unternehmenskultur im Krankenhaus mit Vorrang einer qualitativ hochwertigen Patientenversorgung; 3) Minimierung von Fehlanreizen im Krankenhausfinanzierungssystem gestützt auf die notwendige Reformierung des fallpauschalbasierten Vergütungssystems; 4) Stärkung der interdisziplinären/interprofessionellen Zusammenarbeit in Aus‑, Fort- und Weiterbildung; 5) Initiierung und Begleitung eines gesellschaftlichen Diskurses zur Überversorgung.

          Translated abstract

          Despite social laws, overtreatment, undertreatment, and incorrect treatment are all present in the German health care system. Overtreatment denotes diagnostic and therapeutic measures that are not appropriate because they do not improve the patients’ length or quality of life, cause more harm than benefit, and/or are not consented to by the patient. Overtreatment can result in considerable burden for patients, their families, the treating teams, and society. This position paper describes causes of overtreatment in intensive care medicine and makes specific recommendations to identify and prevent it. Recognition and avoidance of overtreatment in intensive care medicine requires measures on the micro-, meso- and macrolevels, especially the following: (1) frequent (re-)evaluation of the therapeutic goal within the treating team while taking the patient’s will into consideration, while simultaneously attending to the patients and their families; (2) fostering a patient-centered corporate culture in the hospital, giving priority to high-quality patient care; (3) minimizing improper incentives in health care financing, supported by reform of the reimbursement system that is still based on diagnose-related groups; (4) strengthening of interprofessional co-operation via education and training; and (5) initiating and advancing a societal discourse on overtreatment.

          Related collections

          Most cited references74

          • Record: found
          • Abstract: found
          • Article: not found

          Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

          Abstract Background World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19). Methods We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry. Results At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan–Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P=0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P=0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P=0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P=0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. Conclusions These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A Surgical Safety Checklist to Reduce Morbidity and Mortality in a Global Population

            New England Journal of Medicine, 360(5), 491-499
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              A New Dimension of Health Care: Systematic Review of the Uses, Benefits, and Limitations of Social Media for Health Communication

              Background There is currently a lack of information about the uses, benefits, and limitations of social media for health communication among the general public, patients, and health professionals from primary research. Objective To review the current published literature to identify the uses, benefits, and limitations of social media for health communication among the general public, patients, and health professionals, and identify current gaps in the literature to provide recommendations for future health communication research. Methods This paper is a review using a systematic approach. A systematic search of the literature was conducted using nine electronic databases and manual searches to locate peer-reviewed studies published between January 2002 and February 2012. Results The search identified 98 original research studies that included the uses, benefits, and/or limitations of social media for health communication among the general public, patients, and health professionals. The methodological quality of the studies assessed using the Downs and Black instrument was low; this was mainly due to the fact that the vast majority of the studies in this review included limited methodologies and was mainly exploratory and descriptive in nature. Seven main uses of social media for health communication were identified, including focusing on increasing interactions with others, and facilitating, sharing, and obtaining health messages. The six key overarching benefits were identified as (1) increased interactions with others, (2) more available, shared, and tailored information, (3) increased accessibility and widening access to health information, (4) peer/social/emotional support, (5) public health surveillance, and (6) potential to influence health policy. Twelve limitations were identified, primarily consisting of quality concerns and lack of reliability, confidentiality, and privacy. Conclusions Social media brings a new dimension to health care as it offers a medium to be used by the public, patients, and health professionals to communicate about health issues with the possibility of potentially improving health outcomes. Social media is a powerful tool, which offers collaboration between users and is a social interaction mechanism for a range of individuals. Although there are several benefits to the use of social media for health communication, the information exchanged needs to be monitored for quality and reliability, and the users’ confidentiality and privacy need to be maintained. Eight gaps in the literature and key recommendations for future health communication research were provided. Examples of these recommendations include the need to determine the relative effectiveness of different types of social media for health communication using randomized control trials and to explore potential mechanisms for monitoring and enhancing the quality and reliability of health communication using social media. Further robust and comprehensive evaluation and review, using a range of methodologies, are required to establish whether social media improves health communication practice both in the short and long terms.
                Bookmark

                Author and article information

                Contributors
                uwe.janssens@sah-eschweiler.de
                Journal
                Med Klin Intensivmed Notfmed
                Med Klin Intensivmed Notfmed
                Medizinische Klinik, Intensivmedizin Und Notfallmedizin
                Springer Medizin (Heidelberg )
                2193-6218
                2193-6226
                1 March 2021
                1 March 2021
                : 1-11
                Affiliations
                [1 ]GRID grid.492036.a, ISNI 0000 0004 0390 6879, Klinik für Anästhesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie, , Klinikum Konstanz, ; Konstanz, Deutschland
                [2 ]GRID grid.10423.34, ISNI 0000 0000 9529 9877, Institut für Geschichte, Ethik und Philosophie der Medizin, , Medizinische Hochschule Hannover, ; Hannover, Deutschland
                [3 ]GRID grid.461820.9, ISNI 0000 0004 0390 1701, Universitätsklinik und Poliklinik für Innere Medizin III, , Universitätsklinikum Halle (Saale), ; Halle (Saale), Deutschland
                [4 ]GRID grid.9764.c, ISNI 0000 0001 2153 9986, Geschäftsbereichs der Medizinethik, , Christian-Albrechts-Universität zu Kiel, ; Kiel, Deutschland
                [5 ]GRID grid.412469.c, ISNI 0000 0000 9116 8976, Institut für Ethik und Geschichte der Medizin, , Universitätsmedizin Greifswald, ; Greifswald, Deutschland
                [6 ]GRID grid.7400.3, ISNI 0000 0004 1937 0650, Institut für Biomedizinische Ethik und Geschichte der Medizin, , Universität Zürich, ; Zürich, Schweiz
                [7 ]Bovenden, Deutschland
                [8 ]GRID grid.6363.0, ISNI 0000 0001 2218 4662, Klinik für Anästhesiologie und Intensivmedizin, , Charité Universitätsmedizin Berlin, ; Berlin, Deutschland
                [9 ]GRID grid.491865.7, ISNI 0000 0001 0338 671X, Patienten- und Angehörigenzentrierte Versorgung (PAV), , Klinik Bavaria, ; Kreischa, Deutschland
                [10 ]GRID grid.7450.6, ISNI 0000 0001 2364 4210, Klinik für Palliativmedizin, , Georg-August-Universität Göttingen, ; Göttingen, Deutschland
                [11 ]Lemgo, Deutschland
                [12 ]GRID grid.7450.6, ISNI 0000 0001 2364 4210, Abteilung für strafrechtliches Medizin- und Biorecht, , Georg-August-Universität Göttingen, ; Göttingen, Deutschland
                [13 ]GRID grid.459927.4, ISNI 0000 0000 8785 9045, Klinik für Akut- und Notfallmedizin, , St.-Antonius-Hospital Eschweiler, ; Eschweiler, Deutschland
                [14 ]GRID grid.411095.8, ISNI 0000 0004 0477 2585, Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital Kinderpalliativzentrum, , Klinikum der Universität München, ; München, Deutschland
                [15 ]GRID grid.6936.a, ISNI 0000000123222966, Ethik der Medizin und Gesundheitstechnologie, , Technische Universität München, ; München, Deutschland
                [16 ]GRID grid.14778.3d, ISNI 0000 0000 8922 7789, Klinik für Anästhesiologie, , Universitätsklinikum Düsseldorf, ; Düsseldorf, Deutschland
                [17 ]GRID grid.506258.c, ISNI 0000 0000 8977 765X, Simulations- und Notfallakademie, , Helios Klinikum Krefeld, ; Krefeld, Deutschland
                [18 ]GRID grid.459927.4, ISNI 0000 0000 8785 9045, Klinik für Innere Medizin und Internistische Intensivmedizin, , St.-Antonius-Hospital Eschweiler, ; Dechant-Deckers-Str. 8, 52249 Eschweiler, Deutschland
                Article
                794
                10.1007/s00063-021-00794-4
                7919250
                33646332
                d3dadef4-19d2-43cd-a5b8-30a009b47146
                © The Author(s) 2021

                Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden.

                Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen.

                Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de.

                History
                : 1 February 2021
                Categories
                Positionspapier

                therapie am lebensende,behandlungsausmaß,patientenversorgung,therapieziel,ärztliche indikation,patientenwille,end of life care,patient care,extent of treatment,therapeutic goal,patient preference

                Comments

                Comment on this article